

## **INFORMATION DISCLOSURE CITATION**

**(Use several sheets if necessary)**

**Atty. Docket No.**

01579-1155

**Applicant**

KOEBERL et al

**Filing Date**

**Serial No.**

10/761,530

January 21, 2004

1652

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

## **TRANSLATION**

\*Examiner /Ganapathiram Raghu/ Date Considered 05/13/2007

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Sheet 2 of 3

INFORMATION DISCLOSURE  
CITATION

(Use several sheets if necessary)

Atty. Docket No.	Serial No.
<b>01579-1155</b>	<b>10/761,530</b>
Applicant	
<b>KOEBERL et al</b>	
Filing Date	TC/A.U.
<b>January 21, 2004</b>	<b>1652</b>

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

/GR/	Sun et al, "Enhanced Efficacy of an AAV Vector Encoding Chimeric, Highly Secreted Acid $\alpha$ -Glucosidase in Glycogen Storage Disease Type II", Molecular Therapy 14(6):822-830 (2006) GenBank Accession No. NM_000477
	Xia et al, "The HIV Tat protein transduction domain improves the biodistribution of $\beta$ -glucuronidase expressed from recombinant viral vectors", Nature Biotechnology 19:640-644 (2001)
	Orii et al, "Defining the Pathway for Tat-mediated Delivery of $\beta$ -Glucuronidase in Cultured Cells and MPS VII Mice", Molecular Therapy 12(2):345-352 (2005)
	Poenaru, L., Approach to Gene Therapy of Glycogenosis Type II (Pompe Disease), Molecular Genetics and Metabolism, 70 (3):163-169 (2000)
	Hirschhorn, R., "Glycogen Storage Disease Type II: Acid .alpha.-Glucosidase (Acid Maltase) Deficiency", The Metabolic and Molecular Bases of Inherited Disease, (77) 11:2443-2464 (1995)
	Barton, N.W., et al., "Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease", Proc. Natl. Acad. Sci, 87:1913-1916 (Mar. 1990)
	Lauer, R.M., "Administration of a Mixture of Fungal Glucosidases to a Patient with Type II Glycogenosis (Pompe's Disease)", Pediatrics, 42:672-676 (1968)
	Van den Hout., et al., "Enzyme therapy for Pompe disease with recombinant human .alpha.-glucosidase from rabbit milk", J. Inherit. Metab. Dis., 24:266-274 (2001)
	Williams, J.C., et al., "Enzyme Replacement in Pompe Disease With an .alpha.-Glucosidase-Low Density Lipoprotein Complex*", Birth Defects: Original Article Series, 16 (1):415-423 (1980)
	Yang, H.W., et al., "Recombinant Human Acid .alpha.-Glucosidase Corrects Acid .alpha.-Glucosidase-Deficient Human Fibroblasts, Quail Fibroblasts, and Quail Myoblasts", Pediatric Research, 43 (3):374-380 (1998)
	Amalfitano, A., et al., "Recombinant human acid .alpha.-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial", Genetics in Medicine, 3 (2):132-138 (2001)
	Ausems, M., et al., "Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling", European Journal of Human Genetics, 7:713-716 (1999)
	Bijvoet, A.G.A., et al., "Recombinant human acid .alpha.-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice", Human Molecular Genetics, 7 (11):1815-1824 (1998)
	Bijvoet, A.G.A., et al., "Human acid .alpha.-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II", Human Molecular Genetics, 8 (12):2145-2153 (1999)
	Brooks, D.A., "Immune Response to Enzyme Replacement Therapy in Lysosomal Storage Disorder Patients and Animal Models", Molecular Genetics and Metabolism, 68:268-275 (1999)
	de Barys, T., et al., "Enzyme Replacement in Pompe Disease: An Attempt with Purified Human Acid .alpha.-Glucosidase*", Birth Defects:Original Article Series, 9 (2):184-190 (1973)
	Fuller, M., et al., "Isolation and characterisation of a recombinant, precursor form of lysosomal acid .alpha.-glucosidase", Eur. J. Biochem, 234:903-909 (1995)
	Hermans, M.M.P., et al., "The effect of a single base pair deletion (.DELTA.T525) and a C1634T missense mutation (pro545leu) on the expression of lysosomal .alpha.-glucosidase in patients with glycogen storage disease type II", Human Molecular Genetics, 3 (12):2213-2218 (1994)
	Hermans, M.M.P., et al., "The conservative substitution Asp-645.fwdarw.Glu in lysosomal .alpha.-glucosidase affects transport and phosphorylation of the enzyme in an adult patient with glycogen-storage disease type II", Biochem. J., 289:687-693 (1993)
/GR/	Hermans, M.M.P., et al., "Identification of a Point Mutation in the Human Lysosomal .alpha.-Glucosidase Gene Causing Infantile Glycogenosis Type II", Biochemical and Biophysical Research Communications, 179 (2):919-926 (1991)

*Examiner	/Ganapathiram Raghu/	Date Considered	05/13/2007
-----------	----------------------	-----------------	------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Sheet 3 of 3

## **INFORMATION DISCLOSURE CITATION**

**(Use several sheets if necessary)**

**Atty. Docket No.**

**Serial No.**

01579-1155

10/761,530

**Applicant**

KOEBERL et al

**Filing Date**

TC/A.U.

**January 21, 2004**

1652

\*Examiner

/Ganapathiram Raghu/

### Date Considered

05/13/2007

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Sheet 1 of 1

APR 11 2007 Attn: Docket No. 2007-1000

**Serial No.**

10/761,530

**INFORMATION DISCLOSURE  
CITATION**

(Use several sheets if necessary)

KOEBERL et al.

**Filing Date**

January 21, 2004

TC/A.U.

## **January**

1032

U.S. PATENT

2000-01-02

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

## **TRANSLATION**

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

\*Examiner

/Ganapathiram Raghul/

### Date Considered

05/13/2007

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.